Wednesday, August 26, 2026
23.2 C
Bengaluru

Not Everything is a Problem to be Solved

As professionals, we are conditioned to be “fixers.” We see a challenge, and our immediate instinct is to find a solution, build a framework, or optimize a process. But one of the most liberating lessons in leadership and career growth is realizing that not everything is a problem to be solved. To avoid burnout and lead effectively, we must learn to differentiate between three distinct realities:

1. Problems

  • What they are: Clear, bounded challenges with a definable root cause.
  • The approach: Solve them. Find the bugs, patch the leaks, and implement strategic solutions.

2. Predicaments

  • What they are: Complex situations with no immediate or favorable solution (e.g., navigating a market recession, balancing a tight budget with high growth demands).
  • The approach: Cope and compromise. You can’t “fix” a macroeconomic shift, but you can manage your response, adapt your expectations, and build resilience.

3. Paradoxes

  • What they are: Seemingly contradictory yet simultaneous truths that will always coexist (e.g., needing to move fast vs. needing to be accurate; fostering autonomy vs. maintaining alignment).
  • The approach: Accept and balance. Paradoxes aren’t meant to be resolved; they are ongoing tensions to be managed through continuous calibration.

The Takeaway
Treating a predicament like a problem leads to frustration.

Treating a paradox like a problem leads to a never-ending game of whack-a-mole.

True maturity—both organizational and personal—lies in knowing when to fix, when to compromise, and when to simply accept.
How do you differentiate between these in your day-to-day work?

References:

  • Smith, W. K. & Lewis, M. W. (2011). Toward a theory of paradox. Academy of Management Review
  • Heifetz, R. et al. (2009). The Practice of Adaptive Leadership
  • Nielsen, R. K. et al. (2023). Navigating Leadership Paradox 

Hot this week

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Topics

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...
spot_img

Related Articles

spot_imgspot_img